Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mankind Pharma has informed that as per the terms and conditions of 3 Debenture Trust Deeds executed on October 10, 2024 between the Catalyst Trusteeship and the Company for the issuance of listed, rated, secured, redeemable, transferable non-convertible debentures aggregating to INR 5,000 crores (‘NCDs’) by the Company in 3 Series, 39.68% equity shares of Bharat Serums and Vaccines, wholly owned subsidiary of the Company (‘BSV’) have been pledged in favour of Catalyst Trusteeship as the Common Security Trustee for the benefit of the holders of the NCDs. The detailed disclosure as required SEBI Listing Regulations for aforesaid is enclosed as Annexure I.
The above information is a part of company’s filings submitted to BSE.